Global Business Reports


Mungo Smith, Kolby Kaller, Marta Armengod

India Life Sciences 2023

April 27, 2023

India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs and is well-regarded for the role it plays in making high-quality medicines and vaccines affordable to the global population. Fueled by domestic and foreign demand, the sector continues to grow; currently a US$50 billion industry, optimistic forecasts project the Indian pharmaceutical industry could reach US$150 billion within a decade.  

Global Business Reports presents a timely review and analysis of the current state of the industry, highlighting innovations throughout the pharmaceutical value chain and including insight into burgeoning subsectors of the life sciences such as nutraceuticals, digital health, and medical devices. Drawing from interviews conducted with over 60 industry leaders, the India Life Sciences 2023 report brings readers up to speed on the country’s key strengths and areas for development within a post-pandemic landscape. 


Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.


United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.



"With mining companies currently enjoying high prices, exceptional production performance and robust supply chains, we anticipate that the sector will continue showing resilience and growth, remaining financially sound in 2023."